share_log

海正药业(600267.SH):克拉屈滨注射液通过仿制药一致性评价

Zhejiang Hisun Pharmaceutical (600267.SH): KeLaqubin Injection passed the consistency evaluation of generic drugs.

Gelonghui Finance ·  Jun 18 06:49

On June 18, Gelunhui reported that its wholly-owned subsidiary, Hanhui Pharmaceutical Co., Ltd., received the Approval Notice of Supplemental Application for Drug Approval from the National Medical Products Administration for the injection of Cladribine, and Hanhui's Cladribine injection, a pharmaceutical product, has passed the consistency evaluation of quality and efficacy of generic drugs. Cladribine injection is used to treat hairy cell leukemia (HCL) with active clinical significance of anemia, neutropenia, thrombocytopenia, and disease-related symptoms after interferon treatment failure.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment